SL Science Holding Ltd

SL Science Holding Ltd is a biomedical company specializing in developing innovative cellular and gene therapies through its subsidiary, SL Bio. The company focuses on advancing regenerative medicine and cancer treatment. SL Science utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues. Key proprietary technologies include Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. For its proprietary Armed-T Therapy, SL Science is engaged in active product design, in-vitro functional testing, and manufacturing process optimization. Armed-T is designed to enhance anti-cancer cytotoxicity by conjugating bispecific antibodies or other effector molecules to immune cells. As of the date of this Report, no formal good laboratory practice (GLP)-compliant in-vivo toxicity studies have been initiated for Armed-T, and no animal data are yet available. For its Gamma Delta T (GDT) Cell Culture Technology, SL Science has developed a proprietary ex-vivo expansion and activation process for T cells derived from peripheral blood mononuclear cells (PBMCs). Development work has included optimization of cytokine stimulation protocols, culture conditions, and scalability assessments. Early-stage in-vitro cytotoxicity assays and in-vivo efficacy studies have demonstrated the ability of expanded GDT cells to kill selected cancer cell lines. However, no formal GLP-compliant in-vivo toxicity studies have been completed for this platform to date. SL Science's business model centers on developing partnerships with biopharmaceutical companies to transform these technologies into commercially viable drugs and cancer treatments.